Rosenblat Mira, Volkova Nina, Coleman Raymond, Aviram Michael
The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences, Rambam Medical Center, Haifa 31096, Israel.
Atherosclerosis. 2007 Dec;195(2):e61-8. doi: 10.1016/j.atherosclerosis.2007.05.012. Epub 2007 Jun 22.
Liposomal glutathione, but not the control liposomes (with no glutathione), dose-dependently inhibited copper ion-induced low density lipoprotein (LDL) and HDL oxidation. As peroxidase activity was found to be present in both LDL and HDL, it has contributed to the anti-oxidative effects of liposomal glutathione. In-vitro, no significant effect of liposomal glutathione on J774 A.1 macrophage cell-line oxidative stress and on cellular cholesterol metabolism was observed. In contrast, in the atherosclerotic apolipoprotein E-deficient (E(0)) mice, consumption of liposomal glutathione (12.5 or 50mg/kg/day, for 2 months), but not control liposomes, resulted in a significant reduction in the serum susceptibility to AAPH-induced oxidation by 33%. Liposomal glutathione (50mg/kg/day) consumption also resulted in an increment (by 12%) in the mice peritoneal macrophages (MPM) glutathione content, paralleled by a significant reduction in total cellular lipid peroxides content (by 40%), compared to placebo-treated mice MPM. MPM paraoxonase 2 activity was significantly increased by 27% and by 121%, after liposomal glutathione consumption (12.5 or 50mg/kg/day, respectively). Analyses of cellular cholesterol fluxes revealed that, liposomal glutathione (12.5mg/kg/day) consumption, decreased the extent of oxidized-LDL (Ox-LDL) uptake by 17% and the cellular cholesterol biosynthesis rate, by 34%, and stimulated HDL-induced macrophage cholesterol efflux, by 19%. Most important, a significant reduction in macrophage cholesterol mass (by 24%), and in the atherosclerotic lesion area (by 30%) was noted. We thus conclude that liposomal glutathione possesses anti-oxidative and anti-atherogenic properties towards lipoproteins and macrophages, leading to attenuation of atherosclerosis development.
脂质体谷胱甘肽而非对照脂质体(不含谷胱甘肽)能剂量依赖性地抑制铜离子诱导的低密度脂蛋白(LDL)和高密度脂蛋白(HDL)氧化。由于在LDL和HDL中均发现有过氧化物酶活性,这有助于脂质体谷胱甘肽的抗氧化作用。在体外,未观察到脂质体谷胱甘肽对J774 A.1巨噬细胞系氧化应激和细胞胆固醇代谢有显著影响。相反,在动脉粥样硬化载脂蛋白E缺陷(E(0))小鼠中,摄入脂质体谷胱甘肽(12.5或50mg/kg/天,持续2个月)而非对照脂质体,导致血清对AAPH诱导氧化的敏感性显著降低33%。与安慰剂处理的小鼠腹腔巨噬细胞(MPM)相比,摄入脂质体谷胱甘肽(50mg/kg/天)还导致小鼠MPM谷胱甘肽含量增加(12%),同时细胞总脂质过氧化物含量显著降低(40%)。摄入脂质体谷胱甘肽(分别为12.5或50mg/kg/天)后,MPM对氧磷酶2活性分别显著增加27%和121%。细胞胆固醇通量分析显示,摄入脂质体谷胱甘肽(12.5mg/kg/天)使氧化型LDL(Ox-LDL)摄取量降低17%,细胞胆固醇生物合成速率降低34%,并使HDL诱导的巨噬细胞胆固醇流出增加19%。最重要的是,观察到巨噬细胞胆固醇含量显著降低(24%),动脉粥样硬化病变面积显著减少(30%)。因此,我们得出结论,脂质体谷胱甘肽对脂蛋白和巨噬细胞具有抗氧化和抗动脉粥样硬化特性,可导致动脉粥样硬化发展的减弱。